Put It in Reverse: Factor Xa Inhibitor Reversal for Intracranial Hemorrhage
hosted byConnect Educate Impact (CEI)
Put It in Reverse: Factor Xa Inhibitor Reversal for Intracranial Hemorrhage is organized by Connect Educate Impact (CEI).
Initial Release Date: January 11, 2023
Planned Expiration Date: January 11, 2026
Description:
Using factor Xa inhibitors to treat VTE and prevent stroke in patients with atrial fibrillation continues to increase. However, major bleeding including intracranial hemorrhage remains a significant risk, and the ideal reversal agent is still unknown. Join our live discussion to compare reversal, safety, and efficacy outcomes when patients were given andexanet alfa or prothrombin complex concentrate.
Objectives:
Upon successful completion of this application-based course, participants should be able to:
• Compare and contrast mechanisms of action, dosing, and side effects for andexanet alfa and prothrombin complex concentrate.
• Discuss the concept of propensity score-overlap weighting.
• Discuss the difference in patient outcomes after intracranial hemorrhage when given andexanet alfa versus prothrombin complex concentrates.
• Analyze limitations for the use of andexanet alfa and prothrombin complex concentrates for factor Xa inhibitor reversal.
• Apply clinical implications of the trial to a patient with apixaban- or rivaroxaban-associated intracranial hemorrhage.
